Article
Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.
Cardiovascular drugs and therapy - 1 Jun 2026
Hamza Mohammad, Karamat Mubashar, Harmouch Khaled M, Alamzaib Sardar M, Jabeen Sidra, Basit Jawad, Bhanushali Karan, Ved Rohan, Rashdi Amna, Almani Muhammad Usman, Syed Moinuddin, Sattar Yasar, Alraies M Chadi
Abstract excerpt
BACKGROUND: Clopidogrel non-responder is a common dilemma in the management of post-percutaneous coronary intervention (PCI) management. Clopidogrel is metabolized by CYP2C19. The genetic variations in CYP2C19 can affect the efficacy and bioavailability of the drug that can be checked via genotype testing of the gene. This study evaluates the impact of genotype versus conventional guided P2Y12 inhibitor therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
